Equities

Oric Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Oric Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.33
  • Today's Change0.50 / 4.62%
  • Shares traded1.00
  • 1 Year change+42.70%
  • Beta1.3192
Data delayed at least 15 minutes, as of Feb 19 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 12-Feb-26
Select bar for recommendation details.
Recommendations12-Feb-26
Buy7
Outperform7
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for ORIC Pharmaceuticals Inc have a median target of 22.00, with a high estimate of 25.00 and a low estimate of 15.00. The median estimate represents a 94.17% increase from the last price of 11.33.
High120.7%25.00
Med94.2%22.00
Low32.4%15.00

Earnings history & estimates in USD

On Nov 13, 2025, ORIC Pharmaceuticals Inc reported 3rd quarter 2025 losses of -0.33 per share. This result exceeded the -0.41 consensus loss of the 12 analysts covering the company and exceeded last year's 3rd quarter results by 32.65%.
The next earnings announcement is expected on May 07, 2026.
Average growth rate+7.86%
ORIC Pharmaceuticals Inc reported annual 2024 losses of -1.83 per share on Feb 18, 2025.
Average growth rate+12.30%
More ▼

Revenue history & estimates in USD

ORIC Pharmaceuticals Inc did not report revenues for the 3rd quarter 2025. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
ORIC Pharmaceuticals Inc did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.